In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as…
December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…